Literature DB >> 11196541

Plasma monocyte chemoattractant protein 1 is a marker for joint inflammation in rheumatoid arthritis.

T Ellingsen1, A Buus, K Stengaard-Pedersen.   

Abstract

OBJECTIVE: Monocyte chemoattractant protein 1 (MCP-1) level in plasma is described as a marker for joint inflammation in rheumatoid arthritis (RA).
METHODS: MCP-1 in plasma and synovial fluid (SF) was quantified by ELISA in 36 RA patients with synovitis of the knee at Day 1 and 30. Disease activity was assessed by the swollen joint count, Ritchie Articular Index (RAI), global assessment, pain on visual analog scale, Health Assessment Questionnaire, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
RESULTS: By linear regression analysis plasma MCP-1 levels correlated significantly with the swollen joint count (Day 1: R = 0.47, p = 0.005; Day 30: R = 0.53, p < 0.001) and the RAI (Day 1: R = 0.37, p = 0.03; Day 30: R = 0.41, p = 0.01). The correlations of swollen joint count and RAI with ESR and CRP were significant only on Day 30 for the ESR (R = 0.40, p = 0.02). No association was found between plasma MCP-1 levels and the ESR/CRP levels. MCP-1 levels in plasma in RA patients were elevated compared to controls (p < 0.001) and MCP-I levels in SF were higher than in plasma (p < 0.001). No correlation was found between SF MCP-1 levels and in vitro migration of mononuclear cells towards SF. MCP-1 appears to participate in the disease process in RA, and plasma MCP-1 may be useful in monitoring joint inflammation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196541

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  The ECM proteoglycan decorin links desmoplasia and inflammation in chronic pancreatitis.

Authors:  J Köninger; N A Giese; M Bartel; F F di Mola; P O Berberat; P di Sebastiano; T Giese; M W Büchler; H Friess
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

2.  MCP1 triggers monocyte dysfunctions during abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis.

Authors:  Zhongyu Xie; Peng Wang; Jinteng Li; Yuxi Li; Shan Wang; Xiaohua Wu; Suhe Sun; Shuizhong Cen; Hongjun Su; Wen Deng; Zhenhua Liu; Yi Ouyang; Yanfeng Wu; Huiyong Shen
Journal:  J Mol Med (Berl)       Date:  2016-12-05       Impact factor: 4.599

3.  Serum chemokines in patients with rheumatoid arthritis treated with etanercept.

Authors:  Piotr Adrian Klimiuk; Stanislaw Sierakowski; Izabela Domyslawska; Justyna Chwiecko
Journal:  Rheumatol Int       Date:  2009-12-19       Impact factor: 2.631

4.  Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders.

Authors:  T Ellingsen; N Hornung; B K Møller; J H Poulsen; K Stengaard-Pedersen
Journal:  Ann Rheum Dis       Date:  2006-08-11       Impact factor: 19.103

5.  Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases.

Authors:  Eric Röhner; Georg Matziolis; Carsten Perka; Bernd Füchtmeier; Timo Gaber; Gerd-Rüdiger Burmester; Frank Buttgereit; Paula Hoff
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

6.  Low-level laser irradiation treatment reduces CCL2 expression in rat rheumatoid synovia via a chemokine signaling pathway.

Authors:  Lin Zhang; Jian Zhao; Noboru Kuboyama; Yoshimitsu Abiko
Journal:  Lasers Med Sci       Date:  2011-05-04       Impact factor: 3.161

7.  The Role of Macrophages in the Response to TNF Inhibition in Experimental Arthritis.

Authors:  Qi-Quan Huang; Robert Birkett; Renee Doyle; Bo Shi; Elyssa L Roberts; Qinwen Mao; Richard M Pope
Journal:  J Immunol       Date:  2017-11-17       Impact factor: 5.422

8.  EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts.

Authors:  R Largo; I Díez-Ortego; O Sanchez-Pernaute; M J López-Armada; M A Alvarez-Soria; J Egido; G Herrero-Beaumont
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

9.  Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis.

Authors:  C Y Ho; C K Wong; E K Li; L S Tam; C W K Lam
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

10.  Blood monocyte chemotactic protein-1 (MCP-1) and adapted disease activity Score28-MCP-1: favorable indicators for rheumatoid arthritis activity.

Authors:  Lieh-bang Liou; Wen-pin Tsai; Chee J Chang; Wan-ju Chao; Meng-hsin Chen
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.